OTCMBLPH
Market cap146kUSD
Dec 18, Last price
0.01USD
Name
Bellerophon Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
29.75%
Rev. gr., 5y
%
Revenues
0k
Net income
-20m
L+11.69%
CFO
-18m
L-22.13%
Profile
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 22,449 | 20,263 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (22,449) | (20,263) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (2,417) | (1,800) | |||||||
Tax Rate | |||||||||
NOPAT | (20,032) | (18,463) | |||||||
Net income | (19,831) 11.69% | (17,756) -28.19% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 203 | 752 | |||||||
Long-term debt | 203 | 1,158 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,433 | 1,000 | |||||||
Net debt | (6,518) | (23,126) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (17,770) | (22,821) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | (40) | ||||||||
FCF | (19,288) | (17,720) | |||||||
| Balance | |||||||||
Cash | 6,924 | 24,736 | |||||||
Long term investments | 300 | ||||||||
Excess cash | 6,924 | 25,036 | |||||||
Stockholders' equity | (251,982) | (232,152) | |||||||
Invested Capital | 254,719 | 254,727 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 9,551 | 9,503 | |||||||
Price | 0.90 -70.97% | 3.10 -53.52% | |||||||
Market cap | 8,596 -70.82% | 29,459 -43.36% | |||||||
EV | 2,078 | 6,333 | |||||||
EBITDA | (22,384) | (20,161) | |||||||
EV/EBITDA | |||||||||
Interest | 135 | 5 | |||||||
Interest/NOPBT | |||||||||